167 related articles for article (PubMed ID: 27025923)
21. Early monitoring for detection of antituberculous drug-induced hepatotoxicity.
Lee CM; Lee SS; Lee JM; Cho HC; Kim WS; Kim HJ; Ha CY; Kim HJ; Kim TH; Jung WT; Lee OJ
Korean J Intern Med; 2016 Jan; 31(1):65-72. PubMed ID: 26767859
[TBL] [Abstract][Full Text] [Related]
22. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial.
de Castro N; Braun J; Charreau I; Lafeuillade A; Viard JP; Allavena C; Aboulker JP; Molina JM;
AIDS Res Ther; 2016; 13():17. PubMed ID: 27042193
[TBL] [Abstract][Full Text] [Related]
23. Spontaneous Fluctuations in Liver Biochemistries in Patients with Compensated NASH Cirrhosis: Implications for Drug Hepatotoxicity Monitoring.
Shamseddeen H; Vilar-Gomez E; Chalasani N; Myers RP; Subramanian GM; Shlevin HH; Allgood AE; Orman ES
Drug Saf; 2020 Mar; 43(3):281-290. PubMed ID: 31907854
[TBL] [Abstract][Full Text] [Related]
24. Can AST/ALT ratio indicate recovery after acute paracetamol poisoning?
McGovern AJ; Vitkovitsky IV; Jones DL; Mullins ME
Clin Toxicol (Phila); 2015 Mar; 53(3):164-7. PubMed ID: 25652258
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and incidence of liver dysfunction and assessment of biomarkers of liver disease in HIV-infected Asian children.
Aurpibul L; Bunupuradah T; Sophan S; Boettiger D; Wati DK; Nguyen LV; Saphonn V; Hansudewechakul R; Chokephaibulkit K; Lumbiganon P; Truong KH; Do VC; Kumarasamy N; Yusoff NK; Razali K; Kurniati N; Fong SM; Nallusamy R; Sohn AH;
Pediatr Infect Dis J; 2015 Jun; 34(6):e153-8. PubMed ID: 25970117
[TBL] [Abstract][Full Text] [Related]
26. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients.
Powles T; Bracarda S; Chen M; Norry E; Compton N; Heise M; Hutson T; Harter P; Carpenter C; Pandite L; Kaplowitz N
Eur J Cancer; 2015 Jul; 51(10):1293-302. PubMed ID: 25899987
[TBL] [Abstract][Full Text] [Related]
27. External validation of the paracetamol-aminotransferase multiplication product to predict hepatotoxicity from paracetamol overdose.
Wong A; Sivilotti ML; Dargan PI; Wood DM; Greene SL
Clin Toxicol (Phila); 2015; 53(8):807-14. PubMed ID: 26175095
[TBL] [Abstract][Full Text] [Related]
28. Tacrolimus therapy causes hepatotoxicity in patients with a history of liver disease.
Ko MS; Choi YH; Jung SH; Lee JS; Kim HS; Lee CH; Kim SG
Int J Clin Pharmacol Ther; 2015 May; 53(5):363-71. PubMed ID: 25740263
[TBL] [Abstract][Full Text] [Related]
29. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program.
Shavadia JS; Sharma A; Gu X; Neaton J; DeLeve L; Holmes D; Home P; Eckel RH; Watkins PB; Granger CB
Clin Trials; 2019 Jun; 16(3):253-262. PubMed ID: 30880443
[TBL] [Abstract][Full Text] [Related]
30. Liver biomarker and in vitro assessment confirm the hepatic origin of aminotransferase elevations lacking histopathological correlate in beagle dogs treated with GABAA receptor antagonist NP260.
Harrill AH; Eaddy JS; Rose K; Cullen JM; Ramanathan L; Wanaski S; Collins S; Ho Y; Watkins PB; Lecluyse EL
Toxicol Appl Pharmacol; 2014 Jun; 277(2):131-7. PubMed ID: 24699182
[TBL] [Abstract][Full Text] [Related]
31. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy.
Tsung I; Dolan R; Lao CD; Fecher L; Riggenbach K; Yeboah-Korang A; Fontana RJ
Aliment Pharmacol Ther; 2019 Oct; 50(7):800-808. PubMed ID: 31309615
[TBL] [Abstract][Full Text] [Related]
32. Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors - A territory-wide cohort study.
Chan SL; Yip TC; Wong VW; Tse YK; Yuen BW; Luk HW; Lui RN; Chan HL; Mok TS; Wong GL
Cancer Med; 2020 Oct; 9(19):7052-7061. PubMed ID: 32780516
[TBL] [Abstract][Full Text] [Related]
33. The existence of a relationship between increased serum alanine aminotransferase levels detected in premarketing clinical trials and postmarketing published hepatotoxicity case reports.
Llanos L; Moreu R; Ortin T; Peiró AM; Pascual S; Bellot P; Barquero C; Francés R; Such J; Pérez-Mateo M; Horga JF; Zapater P
Aliment Pharmacol Ther; 2010 Jun; 31(12):1337-45. PubMed ID: 20331578
[TBL] [Abstract][Full Text] [Related]
34. Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients.
Zarrabi K; Wu S
Oncology; 2018; 94(5):259-273. PubMed ID: 29539626
[TBL] [Abstract][Full Text] [Related]
35. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
[TBL] [Abstract][Full Text] [Related]
36. Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests.
Merz M; Fettiplace A; Marcinak J; Tillmann HL; Rockey DC; Kullak-Ublick GA
Expert Opin Drug Saf; 2024 Apr; 23(4):527-537. PubMed ID: 38482670
[TBL] [Abstract][Full Text] [Related]
37. Pretreatment data is highly predictive of liver chemistry signals in clinical trials.
Cai Z; Bresell A; Steinberg MH; Silberg DG; Furlong ST
Drug Des Devel Ther; 2012; 6():359-69. PubMed ID: 23226004
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and predictive performance and standardized threshold of traditional biomarkers for drug-induced liver injury in rats.
Tonomura Y; Kato Y; Hanafusa H; Morikawa Y; Matsuyama K; Uehara T; Ueno M; Torii M
J Appl Toxicol; 2015 Feb; 35(2):165-72. PubMed ID: 25186495
[TBL] [Abstract][Full Text] [Related]
39. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis.
Sokolove J; Strand V; Greenberg JD; Curtis JR; Kavanaugh A; Kremer JM; Anofrei A; Reed G; Calabrese L; Hooper M; Baumgartner S; Furst DE;
Ann Rheum Dis; 2010 Sep; 69(9):1612-7. PubMed ID: 20448284
[TBL] [Abstract][Full Text] [Related]
40. Results from a 2-year centralized tolcapone liver enzyme monitoring program.
Lew MF; Kricorian G
Clin Neuropharmacol; 2007; 30(5):281-6. PubMed ID: 17909306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
